Pegilodecakin, the first-in-class drug currently in clinical trials, has shown promising results and may hold potential to provide a new treatment avenue for patients with non-small cell lung cancer (NSCLC) and kidney cancer.
The study, led by The University of Texas MD Anderson Cancer Center, demonstrated that the drug, in combination with two leading anti-PD-1 monoclonal antibodies, pembrolizumab and nivolumab, achieved measurable responses for these patients.
Findings from a multi-center ...
Pegilodecakin, the first-in-class drug currently in clinical trials, has shown promising results and may hold potential to provide a new treatment avenue for patients with non-small cell lung cancer (NSCLC) and kidney cancer.
The study, led by The University of Texas MD Anderson Cancer Center, demonstrated that the drug, in combination with two leading anti-PD-1 monoclonal antibodies, pembrolizumab and nivolumab, achieved measurable responses for these patients.
Findings from a multi-center ...